FGF2 and ductal breast carcinoma in situ: 1d). Furthermore, the FGFR1 signaling activated by AP20187 and bFGF treatments also significantly increased FOXQ1 mRNA expression in DCIS-iFGFR1 cells (lines #1 and #2) and MDA-MB-231 cells, respectively (Fig.